Nakamoto Inc. (NAKA) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $0.20 (+10.79%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Sep 3, 2025 | Matthew Galinko | Maxim Group | $8.00 | +4000.5% |
Top Analysts Covering NAKA
NAKA vs Sector & Market
| Metric | NAKA | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.24 | 2.41 |
| Analyst Count | 3 | 8 | 18 |
| Target Upside | +4000.5% | +1145.3% | +14.9% |
| P/E Ratio | -0.71 | 6.87 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $42M | $47M | $51M | 1 |
| 2027-12-31 | $56M | $61M | $67M | 1 |
| 2028-12-31 | $44M | $48M | $52M | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $0.02 | $0.02 | $0.02 | 1 |
| 2027-12-31 | $0.03 | $0.04 | $0.04 | 1 |
| 2028-12-31 | $0.03 | $0.03 | $0.03 | 1 |
Frequently Asked Questions
What is the analyst consensus for NAKA?
The consensus among 3 analysts covering Nakamoto Inc. (NAKA) is Buy with an average price target of $8.00.
What is the highest price target for NAKA?
The highest price target for NAKA is $8.00, set by Matthew Galinko at Maxim Group on 2025-09-03.
What is the lowest price target for NAKA?
The lowest price target for NAKA is $8.00, set by Matthew Galinko at Maxim Group on 2025-09-03.
How many analysts cover NAKA?
3 analysts have issued ratings for Nakamoto Inc. in the past 12 months.
Is NAKA a buy or sell right now?
Based on 3 analyst ratings, NAKA has a consensus rating of Buy (2.00/5) with a +4000.5% upside to the consensus target of $8.00.
What are the earnings estimates for NAKA?
Analysts estimate NAKA will report EPS of $0.02 for the period ending 2026-12-31, with revenue estimated at $47M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.